Teva Must Pay Baxter’s $144M Hepatitis Damages: Judge

Law360, New York (September 20, 2011, 5:45 PM EDT) -- A Delaware judge on Thursday upheld an arbitration panel's ruling that an indemnity agreement obligates Teva Pharmaceuticals USA Inc. to pay Baxter Healthcare Corp.'s damages — at least $144 million — in sweeping litigation blaming the drugmakers' marketing of anesthetic Propofol for a hepatitis C outbreak.

In May 2010, the first of many Propofol-related suits to go to trial resulted in $500 million punitive damages against the two companies — including $144 million against Baxter, according to the complaint. That lawsuit involved the headmaster of a...
To view the full article, register now.